All
Opdivo Plus Chemo Did Not Improve Progression in EGFR-Mutated NSCLC
February 8th 2024Treatment with Opdivo (nivolumab) and chemotherapy did not significantly improve progression-free survival when compared with chemotherapy alone among some patients with EGFR-mutated metastatic non-small-cell lung cancer.
Tagrisso After Chemoradiation Reduced Progression Risk in NSCLC
February 7th 2024Treatment with Tagrisso after chemoradiation resulted in patients with EGFR-mutant stage 3 non-small cell lung cancer being nearly three times less likely to experience disease progression when compared with those treated with Imfinzi or subject to observation.